We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being de... Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease. Show more
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
- THRIVE VRDN-001 global phase 3 clinical trial in active thyroid eye disease (TED) completed and exceeded its target for enrollment in March 2024; topline readout expected in September 2024...
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will...
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...
Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “company” or “Viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare...
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.6 | -4.27046263345 | 14.05 | 15.44 | 13.34 | 742279 | 14.34378075 | CS |
| 4 | -1.64 | -10.8681245858 | 15.09 | 15.76 | 12.2 | 868930 | 14.15041734 | CS |
| 12 | -4.57 | -25.3607103219 | 18.02 | 21.46 | 12.2 | 919954 | 16.57549126 | CS |
| 26 | -1.92 | -12.4918672739 | 15.37 | 24.18 | 12.2 | 913398 | 18.20009951 | CS |
| 52 | -10.02 | -42.6927993183 | 23.47 | 28.35 | 10.925 | 829490 | 18.45329579 | CS |
| 156 | -3.75 | -21.8023255814 | 17.2 | 39 | 9.47 | 521700 | 20.4154398 | CS |
| 260 | -7.94 | -37.1201496026 | 21.39 | 39 | 9.47 | 473966 | 20.39538839 | CS |
Apprentice
3 years ago
Apprentice
3 years ago
crudeoil24
3 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
